How to Buy Ptc Therapeutics Stock
Ptc Therapeutics Inc
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders.
Ptc Therapeutics stock last closed at $64.46, up 2.28% from the previous day, and has decreased 4.29% in one year. It has overperformed other stocks in the Biotechnology industry by 0.62 percentage points. Ptc Therapeutics stock is currently +9.63% from its 52-week low of $58.80, and -29.06% from its 52-week high of $90.86.
As of Oct 29, 2026, there are 83.46M PTCT shares outstanding. The market cap of PTCT is $5.38B. In the past 24 hours, 1.52M PTCT shares were traded.
How to Buy Ptc Therapeutics Stock
Not sure how to invest in Ptc Therapeutics stock? Here's how.
- Choose where to buy Ptc Therapeutics stock: You need to pick an online brokerage, but don't worry - we've sifted through dozens of online stock brokerages and apps to help you figure out where to buy Ptc Therapeutics stock.
- Create your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've selected.
- Deposit money your brokerage account: Choose your method of payment and add your information.
- Research Ptc Therapeutics stock: The Ptc Therapeutics ticker symbol is PTCT. Is Ptc Therapeutics stock a good investment? Should you buy shares of PTCT? How do PTCT's underlying business fundamentals look? Do top analysts think Ptc Therapeutics is a good buy? Why has PTCT's stock price moved recently? (Hint: Our stock market research website can help you decide if PTCT is a good stock to buy).
- Make your PTCT trade: Decide if you will purchase PTCT shares at the current market price or use a limit order to purchase PTCT stock at a given price.
- Get the latest scoop on your PTCT investment: Create a watchlist to important updates regarding your position in Ptc Therapeutics stock.
Step 1: Choose where to buy Ptc Therapeutics stock
You need a brokerage account to access the NASDAQ market and buy PTCT shares.
Our preferred brokerage: eToro
Based on our analysis, eToro is the best place to buy stocks. eToro gives you:
- Invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to world financial markets: From Tech to Industrials, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading exchanges.
- Social investing: eToro has a community of more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your purchase of stock by signing up for an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Create your brokerage account
Now that you've picked the right brokerage, you'll need to fill out some personal information so you are able to invest in PTCT stock today.
How to Create a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal details to open a new trading account.
- Send your information by pressing the "Create Account" button. Get started with eToro today
Step 3: Deposit money your brokerage account
Now that you've filled out your info on a mobile trading app, you need to deposit funds:
Check out the video below if you need help depositing money into your new brokerage account.
Step 4: Research Ptc Therapeutics stock
Once you have selected the best place to buy Ptc Therapeutics stock, it's crucial to research their stock before you buy, so you truly comprehend the risk as well as the opportunity.
Ptc Therapeutics stock at a glance
Ptc Therapeutics Due Diligence Score
WallStreetZen was designed to help part-time investors do better fundamental analysis in less time.
You can see all of the due diligence checks on PTCT's stock page.
Is PTCT stock undervalued?
Analysts use many financial metrics, analyses, models, and charts to gauge PTCT's true value.
You can access more valuation research on PTCT's stock here.
A look at PTCT Cashflows and Balance Sheet
Positive Health Checks:
- PTCT has $2.23B in cash and short term investments. This is sufficient to cover its annual cash burn of $39.71M.
- There are more short-term assets than short-term liabilities on the PTCT balance sheet.
- PTCT has cash burn of 39711000. It has enough cash and short-term investments to cover this for at least one year.
Negative Health Checks:
- PTCT debt to equity ratio of -20.66 is negative.
- Total PTCT debt is still negative.
- PTCT profit margin has gone down from 35.6% to -3.8% in the past year.
- There are more long-term liabilities than short-term assets on the PTCT balance sheet.
Is it a good time to buy PTCT stock, according to analysts?
Out of 9 Wall Street analysts who monitor PTCT, the consensus analyst rating on Ptc Therapeutics is a Strong Buy
It's important to keep in mind that analyst ratings are not recommendations, nor are they financial advice.
Latest PTCT Analyst Upgrades/Downgrades
Benjamin Burnett, a bottom 5% analyst from Wells Fargo maintains PTCT with a strong buy rating and raises their PTCT price target from $106.00 to $109.00, on Aug 13, 2026.
Wells Fargo's Benjamin Burnett raised their price target on Ptc Therapeutics (NASDAQ: PTCT) by 2.8% from $106 to $109 on 2026/08/13. The analyst maintained their Strong Buy rating on the stock.
PTC Therapeutics reported its Q2 2026 earnings.
Raising their price target after meeting with management, Burnett made the following points:
- They believe two themes dominate the stock: (1) Sephience expectations, and (2) "what's next."
- Management showed confidence in Sephience with commentary that was consistent with feedback received from key opinion leaders.
- Wells Fargo expects U.S. adoption to increase at a steady rate for the near term.
- Regarding "what's next?," their firm sees the potential for NLRP3/MSH3/AA feedback on voto to create a holding opportunity that will reward long-term investors for owning the stock today.
Earnings Report
For Q2 2026, PTC Therapeutics reported:
- EPS of $0.92, which beat the Zacks Consensus Estimate of $(0.17) and Q2 2025's $(0.83).
- Revenue of $360.52M, which beat the Zacks Consensus Estimate by 22.24% and Q2 2025's $178.88M.
For FY 2026, management guided:
Total revenue of $1.18B to $1.28B.
- Total product revenue of $850M to $950M, up from the prior $750M to $850M.
CEO Matthew B. Klein, M.D., commented: "Our teams delivered another strong quarter enabling us to again raise 2026 product revenue guidance.
"We also made a number of advances in our R&D pipeline, including identification of our next small molecule splicing development candidate, PTC303, targeting somatic expansion disorders including Huntington's disease and myotonic dystrophy.
"In addition, we initiated the Phase 1 study of PTC612, our differentiated NLRP3 small molecule."
Jeffrey Hung, a top 7% analyst from Morgan Stanley maintains PTCT with a strong buy rating and raises their PTCT price target from $93.00 to $104.00, on Jul 31, 2026.
Geoff Meacham, a top 6% analyst from Citigroup assumes PTCT with a strong buy rating and raises their PTCT price target from $75.00 to $108.00, on Jun 9, 2026.
Faisal Khurshid, a top 6% analyst from Jefferies upgrades PTCT to a strong buy rating and raises their PTCT price target from $76.00 to $85.00, on May 27, 2026.
Joseph Thome, a bottom 4% analyst from TD Cowen upgrades PTCT to a strong buy rating and raises their PTCT price target from $75.00 to $90.00, on May 8, 2026.
You can dig deeper into what analysts are forecasting on the Ptc Therapeutics stock forecast page.
PTCT Trading Indicators
Is PTCT Making Money?
Last year, PTCT revenue was $1.01B. In the past five year, PTCT's revenue has grown by 16.41% per year. This was slower than the Biotechnology industry average of 30.58%.
Learn more about PTCT's earnings and revenue performance here.
Who is buying/selling PTCT?
In the last year, insiders at PTCT have sold more shares than they have bought.
Michael Schmertzler, Director of PTCT, was the latest PTCT insider to sell. They sold $126,063.36 worth of PTCT stock on Oct 14, 2026.
Learn more about who owns PTCT stock here.
Does PTCT stock generate passive income?
No, Ptc Therapeutics doesn't provide an income stream by paying out dividends.
Get opinions from other traders
One of the biggest reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other investors have to say.
Step 5: Make your PTCT trade
You have two primary order types:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are usually sufficient. - Limit order: A limit order lets you buy or sell a stock at a specific price (or better).
If you want to ensure you're buying or selling at a particular dollar amount, place a limit order.
Press the Open button and your broker will place the order.
If you want more assistance buying stocks on eToro, click the how to video below:
Step 6: Get the latest scoop on your PTCT investment
Now that you own some PTCT shares, you'll want to keep up with your investment.
Create a watchlist to track the most important metrics related to your PTCT stock.
PTCT Feed
How to Buy Stock in Ptc Therapeutics
To reiterate, here are the 6 steps to buy stock in Ptc Therapeutics:
- Choose where to buy Ptc Therapeutics stock
- Create your brokerage account
- Deposit money your brokerage account
- Research Ptc Therapeutics stock
- Make your PTCT trade
- Get the latest scoop on your PTCT investment
If you require a brokerage account, eToro is our favorite venue.
Get Started with eToro TodayIf you want to get updates on your new investment in Ptc Therapeutics, create a watchlist today.
Other Stock Buying Guides You May Find Useful
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.